The Competition Commission of India has approved three major combinations.
In a tweet, CCI said it had approved RPG Life Sciences acquiring seven brands of Sun Pharmaceutical Industries. Earlier this year, Sun Pharmaceutical had signed a deal in this regard with RPG, for Rs 41 crore. The move is in line with the company’s strategy to focus on formulations. The acquired brands are primarily in the respiratory and urology segments.
In another tweet, CCI said it had approved the proposed restructuring of Fortis Group, which includes de-merger of the pathology business, SRL Labs. The latter would be merged with Fortis Malar Hospitals and the entity renamed SRL Ltd, to be listed on the National Stock Exchange.
Fortis’ board approved the de-merger in August. Once through, all the group’s diagnostics business would come under the entity which is currently Fortis Malar. The latter’s hospitals business will be sold to Fortis Healthcare. For the composite scheme, Fortis Malar would issue and allot 0.98 fully paid-up equity shares of Rs 10 each for every one equity share of Rs 10 each held by them in Fortis Healthcare.
Full Content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI